PL2296464T3 - Sole i polimorfy związku tetracyklinowego - Google Patents

Sole i polimorfy związku tetracyklinowego

Info

Publication number
PL2296464T3
PL2296464T3 PL09751737T PL09751737T PL2296464T3 PL 2296464 T3 PL2296464 T3 PL 2296464T3 PL 09751737 T PL09751737 T PL 09751737T PL 09751737 T PL09751737 T PL 09751737T PL 2296464 T3 PL2296464 T3 PL 2296464T3
Authority
PL
Poland
Prior art keywords
tetraccline
polymorphas
salts
compound
tetraccline compound
Prior art date
Application number
PL09751737T
Other languages
English (en)
Inventor
Raymond Cvetovich
Tadeusz Warchol
Original Assignee
Paratek Pharm Innc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharm Innc filed Critical Paratek Pharm Innc
Publication of PL2296464T3 publication Critical patent/PL2296464T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/10—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type
    • G02B6/12—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
    • G02B6/122—Basic optical elements, e.g. light-guiding paths
    • G02B6/1223—Basic optical elements, e.g. light-guiding paths high refractive index type, i.e. high-contrast waveguides
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/10—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type
    • G02B6/12—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
    • G02B6/13—Integrated optical circuits characterised by the manufacturing method
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
    • C07C2603/44—Naphthacenes; Hydrogenated naphthacenes
    • C07C2603/46—1,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/10—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type
    • G02B6/12—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
    • G02B2006/12035—Materials
    • G02B2006/12038—Glass (SiO2 based materials)
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/10—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type
    • G02B6/12—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
    • G02B2006/12083—Constructional arrangements
    • G02B2006/12119—Bend
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/24—Coupling light guides
    • G02B6/26—Optical coupling means
    • G02B6/28—Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals
    • G02B6/2804—Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals forming multipart couplers without wavelength selective elements, e.g. "T" couplers, star couplers
    • G02B6/2861—Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals forming multipart couplers without wavelength selective elements, e.g. "T" couplers, star couplers using fibre optic delay lines and optical elements associated with them, e.g. for use in signal processing, e.g. filtering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Nanotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
PL09751737T 2008-05-19 2009-05-26 Sole i polimorfy związku tetracyklinowego PL2296464T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12871208P 2008-05-19 2008-05-19
PCT/US2009/045143 WO2009143509A1 (en) 2008-05-19 2009-05-26 Salts and polymorphs of a tetracycline compound
EP09751737.9A EP2296464B1 (en) 2008-05-19 2009-05-26 Salts and polymorphs of a tetracycline compound

Publications (1)

Publication Number Publication Date
PL2296464T3 true PL2296464T3 (pl) 2015-08-31

Family

ID=41340587

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14156670T PL2807926T3 (pl) 2008-05-19 2009-05-26 Sole i polimorfy związku tetracyklinowego
PL09751737T PL2296464T3 (pl) 2008-05-19 2009-05-26 Sole i polimorfy związku tetracyklinowego

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL14156670T PL2807926T3 (pl) 2008-05-19 2009-05-26 Sole i polimorfy związku tetracyklinowego

Country Status (30)

Country Link
US (5) US8383610B2 (pl)
EP (3) EP2807926B1 (pl)
JP (7) JP5727930B2 (pl)
KR (1) KR101679362B1 (pl)
CN (4) CN105348138A (pl)
AR (1) AR075447A1 (pl)
AU (2) AU2009248795B2 (pl)
BR (1) BRPI0913026B1 (pl)
CA (2) CA2724897C (pl)
CO (1) CO6300898A2 (pl)
CY (2) CY1116436T1 (pl)
DK (2) DK2807926T3 (pl)
EC (1) ECSP10010704A (pl)
ES (2) ES2842204T3 (pl)
HR (2) HRP20150584T1 (pl)
HU (1) HUE053038T2 (pl)
IL (1) IL209414A0 (pl)
LT (1) LT2807926T (pl)
MA (1) MA32407B1 (pl)
MX (1) MX2010012622A (pl)
MY (1) MY156254A (pl)
NZ (2) NZ598154A (pl)
PL (2) PL2807926T3 (pl)
PT (2) PT2296464E (pl)
RU (1) RU2500665C2 (pl)
SI (2) SI2296464T1 (pl)
TN (1) TN2010000539A1 (pl)
TW (7) TW202332671A (pl)
WO (1) WO2009143509A1 (pl)
ZA (2) ZA201008390B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2213655A1 (en) * 2007-04-27 2010-08-04 Paratek Pharmaceuticals, Inc. Methods For Purifying Aminoalkyl Tetracycline Compounds
AU2009220171A1 (en) 2008-03-05 2009-09-11 Paratek Pharmaceuticals, Inc. Minocycline compounds and methods of use thereof
TW202332671A (zh) * 2008-05-19 2023-08-16 美商Ｐｒｔｋ Ｓｐｖ２公司 四環素化合物之甲苯磺酸鹽及同素異形體
EP3574908B8 (en) 2011-05-12 2024-09-11 Almirall LLC Pharmaceutical composition for oral administration comprising crystalline salts of (4s, 4as, 5ar, 12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2carboxylic acid amide
PT108223B (pt) 2015-02-13 2018-05-08 Hovione Farm S A Novas formas polimórficas de minociclina base e processos para a sua preparação
JP6793715B2 (ja) 2015-03-23 2020-12-02 バイオファーミクス・インコーポレイテッドＢｉｏＰｈａｒｍＸ， Ｉｎｃ． テトラサイクリンの皮膚用医薬組成物
SG11201808246SA (en) * 2016-03-24 2018-10-30 Paratek Pharm Innc Methods for treating and preventing c. difficile infection
MX2018013271A (es) * 2016-05-02 2019-03-28 Paratek Pharm Innc Compuestos 9-aminometil minociclina y metodos para utilizarlos en el tratamiento de infeccion de vias urinarias (ivu).
RU2764723C2 (ru) * 2016-06-22 2022-01-19 Кбп Байосайенсиз Ко., Лтд. Кристаллические формы 9-аминометил-замещенного соединения тетрациклина и способ их получения
TWI746610B (zh) * 2016-08-03 2021-11-21 美商派瑞泰Ｓｐｖ２有限公司 9-胺甲基米諾四環素化合物及其用途
WO2018066427A1 (ja) * 2016-10-03 2018-04-12 株式会社セレステ Ｔｒｈアナログ及びアルンド酸を組み合わせてなる組成物、並びにアルンド酸の薬学的に許容される塩
HRP20240605T1 (hr) * 2016-10-19 2024-07-19 Tetraphase Pharmaceuticals, Inc. Kristalni oblici eravaciklina
US10383884B2 (en) 2016-11-01 2019-08-20 Paratek Pharmaceuticals, Inc. 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
RU2632708C1 (ru) * 2016-11-14 2017-10-09 Лонг Шенг Фарма Лимитед Способ получения комбинированного антибактериального препарата
EP3846805A4 (en) 2018-09-04 2022-08-24 Paratek Pharmaceuticals, Inc. Methods of treating mycobacterial infections using tetracycline compounds
CN111484424B (zh) * 2020-04-14 2022-10-25 成都百特万合医药科技有限公司 一种合成奥马环素的方法
JP2023530415A (ja) * 2020-06-11 2023-07-18 パラテック ファーマシューティカルズ，インコーポレイテッド オマダサイクリンの結晶形態、その合成方法及びその使用方法
PT117254B (pt) 2021-05-26 2024-04-18 Hovione Farm S A Método de síntese de compostos 9-aminometil tetraciclinas
CN113433249B (zh) * 2021-07-21 2023-03-24 河北圣雪大成制药有限责任公司 一种高效液相色谱法检测米诺环素中间体有关物质的方法
CN113929593B (zh) * 2021-09-02 2024-05-31 河北圣雪大成唐山制药有限责任公司 一种土霉素-2,5-二羟基苯甲酸共晶及其制备方法
WO2023047323A1 (en) * 2021-09-24 2023-03-30 Glenmark Life Sciences Limited Process for the preparation of omadacycline tosylate
CN121627532A (zh) * 2024-09-06 2026-03-10 上海迪赛诺化学制药有限公司 一种奥马环素的制备方法
CN119751292A (zh) * 2024-12-30 2025-04-04 重庆圣华曦药业股份有限公司 一种甲苯磺酸奥玛环素的精制方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990331A (en) 1956-11-23 1961-06-27 Pfizer & Co C Stable solutions of salts of tetracyclines for parenteral administration
US2980584A (en) 1957-10-29 1961-04-18 Pfizer & Co C Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation
US3062717A (en) 1958-12-11 1962-11-06 Pfizer & Co C Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation
US3019260A (en) 1959-05-13 1962-01-30 American Cyanamid Co Process for the catalytic reduction of 6-hydroxy hydronaphthacenes
FR1430859A (pl) 1960-05-23 1966-05-25
US3165531A (en) 1962-03-08 1965-01-12 Pfizer & Co C 13-substituted-6-deoxytetracyclines and process utilizing the same
DK122658B (da) * 1963-06-17 1972-03-27 Novo Terapeutisk Labor As Fremgangsmåde til udfældning af tetracyclinbase i krystallinsk form.
US3454697A (en) 1965-06-08 1969-07-08 American Cyanamid Co Tetracycline antibiotic compositions for oral use
US3304227A (en) 1965-07-15 1967-02-14 Loyal E Loveless Antibiotic-containing animal feed
NL6607516A (pl) 1966-05-31 1967-12-01
DE1767891C3 (de) 1968-06-28 1980-10-30 Pfizer Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat
CA999855A (en) * 1972-09-18 1976-11-16 Societa' Farmaceutici Italia S.P.A. Process for the preparation of tetracyclines derivatives in the 7 position
US3957980A (en) 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
DE2442829A1 (de) 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
US4018889A (en) 1976-01-02 1977-04-19 Pfizer Inc. Oxytetracycline compositions
US4126680A (en) 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
US4935412A (en) 1983-12-29 1990-06-19 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4704383A (en) 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
USRE34656E (en) 1983-12-29 1994-07-05 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency
US4666897A (en) 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
US4925833A (en) 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
JP3016587B2 (ja) 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 非ステロイド抗炎症剤及びテトラサイクリンの配合
US5308839A (en) 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
DE4042402C1 (pl) 1990-10-03 1992-09-03 Degussa Ag, 6000 Frankfurt, De
US5770588A (en) 1991-02-11 1998-06-23 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions of the prevention and treatment of root caries
US5231017A (en) 1991-05-17 1993-07-27 Solvay Enzymes, Inc. Process for producing ethanol
US5494903A (en) 1991-10-04 1996-02-27 American Cyanamid Company 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
ES2168254T3 (es) 1991-10-04 2002-06-16 American Cyanamid Co Nuevas 7-sustituidas-9-(amino sustituido)-6-desmetil-6-desoxitetraciclinas.
US5258371A (en) 1992-05-29 1993-11-02 Kuraray Co., Ltd. Method to reduce connective tissue destruction
US6043225A (en) 1992-06-12 2000-03-28 Board Of Regents Of The University Of Washington Diagnosis and treatment of arterial chlamydial granuloma
EP0599397B1 (en) 1992-11-17 1996-08-28 The Research Foundation Of State University Of New York Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive collagen crosslinking during diabetes
US6043231A (en) 1993-03-02 2000-03-28 The Research Foundation Of State Univ. Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5523297A (en) 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5668122A (en) 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
AU1279095A (en) 1994-02-17 1995-09-04 Pfizer Inc. 9-(substituted amino)-alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics
US5843925A (en) 1994-12-13 1998-12-01 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5834449A (en) 1996-06-13 1998-11-10 The Research Foundation Of State University Of New York Treatment of aortic and vascular aneurysms with tetracycline compounds
US5827840A (en) 1996-08-01 1998-10-27 The Research Foundation Of State University Of New York Promotion of wound healing by chemically-modified tetracyclines
US5789395A (en) 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
US5773430A (en) 1997-03-13 1998-06-30 Research Foundation Of State University Of New York Serine proteinase inhibitory activity by hydrophobic tetracycline
US6277067B1 (en) 1997-04-04 2001-08-21 Kerry L. Blair Method and portable colposcope useful in cervical cancer detection
US5929055A (en) 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
US6277061B1 (en) 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
US6015804A (en) 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
US5998390A (en) 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
CA2351703C (en) 1998-11-18 2008-12-30 Collagenex Pharmaceuticals, Inc. Novel 4-dedimethylaminotetracycline derivatives
DE19938198A1 (de) * 1999-08-12 2001-03-01 Deutsche Telekom Ag Verfahren zum Etablieren eines gemeinsamen Schlüssels für eine Gruppe von mindestens drei Teilnehmern
US6231894B1 (en) 1999-10-21 2001-05-15 Duke University Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
US7231517B1 (en) * 2000-03-03 2007-06-12 Novell, Inc. Apparatus and method for automatically authenticating a network client
CN1450989A (zh) * 2000-07-07 2003-10-22 塔夫茨大学信托人 7－取代的四环素化合物
KR100674047B1 (ko) 2000-07-07 2007-01-25 트러스티즈 오브 터프츠 칼리지 9-치환된 미노사이클린 화합물
IL157860A0 (en) 2001-03-13 2004-03-28 Paratek Pharm Innc 7,9-substituted tetracycline compounds
US7553828B2 (en) 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
US20030021841A1 (en) * 2001-07-02 2003-01-30 Matharu Amol Singh Pharmaceutical composition
WO2003075857A2 (en) * 2002-03-08 2003-09-18 Paratek Pharmaceuticals, Inc. Amino-methyl substituted tetracycline compounds
JP4099039B2 (ja) * 2002-11-15 2008-06-11 松下電器産業株式会社 プログラム更新方法
US20060287283A1 (en) * 2003-07-09 2006-12-21 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
JP4712325B2 (ja) * 2003-09-12 2011-06-29 株式会社リコー 通信装置、通信システム、通信方法及びプログラム
US8015399B2 (en) * 2003-09-30 2011-09-06 Ricoh Company, Ltd. Communication apparatus, communication system, certificate transmission method and program
JP4621200B2 (ja) * 2004-04-15 2011-01-26 パナソニック株式会社 通信装置、通信システム及び認証方法
AR057649A1 (es) * 2005-05-27 2007-12-12 Wyeth Corp Formas solidas cristalinas de tigeciclina y metodos para preparar las mismas
EP2298324A1 (en) * 2006-01-24 2011-03-23 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
ES2622356T3 (es) * 2006-04-24 2017-07-06 Teva Pharmaceutical Industries, Ltd. Formas cristalinas de tigeciclina y procesos para su preparación
CN101134733A (zh) * 2007-09-24 2008-03-05 合肥信风科技开发有限公司 一种替加环素的物质形态及其制备方法
AU2009220171A1 (en) * 2008-03-05 2009-09-11 Paratek Pharmaceuticals, Inc. Minocycline compounds and methods of use thereof
PT2271348T (pt) * 2008-03-28 2018-04-16 Paratek Pharm Innc Formulação de comprimido oral de composto de tetraciclina
TW202332671A (zh) * 2008-05-19 2023-08-16 美商Ｐｒｔｋ Ｓｐｖ２公司 四環素化合物之甲苯磺酸鹽及同素異形體

Also Published As

Publication number Publication date
CY1123705T1 (el) 2022-03-24
IL209414A0 (en) 2011-01-31
MY156254A (en) 2016-01-29
JP2021011498A (ja) 2021-02-04
US9227921B2 (en) 2016-01-05
TW202542107A (zh) 2025-11-01
BRPI0913026B1 (pt) 2022-03-03
AR075447A1 (es) 2011-04-06
CN102105058B (zh) 2015-11-25
CN102105058A (zh) 2011-06-22
EP2296464B1 (en) 2015-03-04
DK2296464T3 (en) 2015-06-15
DK2807926T3 (da) 2021-01-11
KR20110022619A (ko) 2011-03-07
HRP20202081T1 (hr) 2021-02-19
KR101679362B1 (ko) 2016-11-25
CN104844472B (zh) 2018-02-13
TW201741281A (zh) 2017-12-01
ZA201400281B (en) 2015-04-29
TW202436282A (zh) 2024-09-16
ES2842204T3 (es) 2021-07-13
AU2009248795A1 (en) 2009-11-26
CO6300898A2 (es) 2011-07-21
TW202021946A (zh) 2020-06-16
US8383610B2 (en) 2013-02-26
EP2807926A1 (en) 2014-12-03
US20260053824A1 (en) 2026-02-26
JP2024169444A (ja) 2024-12-05
JP2015166350A (ja) 2015-09-24
JP2019052184A (ja) 2019-04-04
EP2296464A1 (en) 2011-03-23
AU2016262682B2 (en) 2018-06-28
US20100113399A1 (en) 2010-05-06
WO2009143509A1 (en) 2009-11-26
CA2724897C (en) 2017-12-19
SI2807926T1 (sl) 2021-03-31
EP2807926B1 (en) 2020-10-07
AU2009248795B2 (en) 2016-08-25
JP2011520988A (ja) 2011-07-21
PL2807926T3 (pl) 2021-05-31
EP3827817A1 (en) 2021-06-02
US20160324879A1 (en) 2016-11-10
CN104844472A (zh) 2015-08-19
US20140005420A1 (en) 2014-01-02
TW202332671A (zh) 2023-08-16
TW201000433A (en) 2010-01-01
NZ589574A (en) 2012-04-27
ZA201008390B (en) 2014-03-26
RU2500665C2 (ru) 2013-12-10
TW202216656A (zh) 2022-05-01
HK1204526A1 (en) 2015-11-27
ES2538364T3 (es) 2015-06-19
US20180104262A1 (en) 2018-04-19
CY1116436T1 (el) 2017-02-08
MX2010012622A (es) 2010-12-21
JP2017149750A (ja) 2017-08-31
HUE053038T2 (hu) 2021-06-28
CN108324722A (zh) 2018-07-27
PT2807926T (pt) 2021-01-12
JP2022189916A (ja) 2022-12-22
RU2010152758A (ru) 2012-06-27
EP2296464A4 (en) 2011-05-18
PT2296464E (pt) 2015-07-13
ECSP10010704A (es) 2011-01-31
MA32407B1 (fr) 2011-06-01
CN105348138A (zh) 2016-02-24
JP5727930B2 (ja) 2015-06-03
BRPI0913026A2 (pt) 2019-08-27
TWI585071B (zh) 2017-06-01
TN2010000539A1 (en) 2012-05-24
CA2724897A1 (en) 2009-11-26
LT2807926T (lt) 2021-02-10
CA2987354A1 (en) 2009-11-26
TWI680117B (zh) 2019-12-21
JP6129235B2 (ja) 2017-05-17
SI2296464T1 (sl) 2015-07-31
NZ598154A (en) 2013-05-31
HK1154757A1 (zh) 2012-05-04
HRP20150584T1 (hr) 2015-07-03
AU2016262682A1 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
PL2807926T3 (pl) Sole i polimorfy związku tetracyklinowego
NL300891I2 (nl) Lotilaner en zouten daarvan
HRP20190509T1 (hr) Spoj piridilaminooctene kiseline
HRP20180718T1 (hr) Oligopeptidni spojevi i njihova upotreba
EP2296593A4 (en) MEDICAL HEAD COVER
DK2288375T3 (da) Pegylerede insulin-lispro-forbindelser
BRPI0920707A2 (pt) compostos
DK2242759T3 (da) Forbindelser
EP2245315A4 (en) O-HEAD DESIGN
BRPI0916432A2 (pt) compostos
BRPI0917718A2 (pt) calçado
DK2206698T3 (da) Ethynylindolforbindelser
BRPI0922152A2 (pt) Compostos
DK2173197T3 (da) Fremgangsmåde
BRPI0913805A2 (pt) composto
BRPI0909764A2 (pt) compostos terapêuticos
BRPI0922134A2 (pt) Compostos
MA30860B1 (fr) Myrtillier denomme "c97-390"
BRPI0906879A2 (pt) Compostos terapêuticos
FI20085267L (fi) Kaivo ja kaivon pohja
FR2937843B1 (fr) Paravent medical
EE200800059A (et) K„siaplikaatori kinnitus
DK2257548T3 (da) Terapeutiske forbindelser
UA16898S (uk) Підошва
UA18207S (uk) Підошва